These drug enrichment results corroborate multiple experimental findings highlighting the therapeutic efficacy of cathepsin inhibitors in a subgroup of MS patients responsive to interferon therapy (Haves-Zburof et al., 2011; Burster et al., 2007). Here, CTSS is linked to myeloid sarcoma.